Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Irsenontrine - Eisai Inc

Next Previous
Drug Profile

Irsenontrine - Eisai Inc

Alternative Names: [14C] E 2027; E 2027; E2027 maleate; ER-000592221-MAL; ER-592221-12; Irsenontrine maleate

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eisai Inc
  • Class 3-ring heterocyclic compounds; Antidementias; Ethers; Furans; Neuroprotectants; Pyrazoles; Pyridines; Quinolines
  • Mechanism of Action Phosphodiesterase 9A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Lewy body disease
  • Phase II Dementia

Most Recent Events

  • 27 Jan 2022 Eisai completes a phase II trial for Lewy Body disease (In adults, In the elderly) in USA and Canada (NCT04764669)
  • 18 Mar 2021 Chemical structure information added
  • 26 Feb 2021 Eisai initiates enrolment in a phase II trial for Lewy Body disease (In adults, In the elderly) in USA (NCT04764669)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top